Publication: Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Final findings from the CONTROL trial
dc.conference.date | MAY 03-05, 2022 | |
dc.conference.title | European-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress | |
dc.contributor.author | Chan, A. | |
dc.contributor.author | Ruiz Borrego, M. | |
dc.contributor.author | Marx, G. | |
dc.contributor.author | Brufsky, A. | |
dc.contributor.author | Chien, A. J. | |
dc.contributor.author | Thirlwell, M. P. | |
dc.contributor.author | Trudeau, M. E. | |
dc.contributor.author | Bose, R. | |
dc.contributor.author | Saenz, J. A. Garcia | |
dc.contributor.author | Egle, D. | |
dc.contributor.author | Pistilli, B. | |
dc.contributor.author | Wassermann, J. | |
dc.contributor.author | Cheong, K. A. | |
dc.contributor.author | Semsek, D. | |
dc.contributor.author | Singer, C. F. | |
dc.contributor.author | Diprimeo, D. | |
dc.contributor.author | Foruzan, N. | |
dc.contributor.author | McCulloch, L. M. | |
dc.contributor.author | Barcenas, C. H. | |
dc.contributor.authoraffiliation | [Chan, A.] Breast Canc Res Ctr BCRC WA, Med Oncol, Nedlands, WA, Australia | |
dc.contributor.authoraffiliation | [Ruiz Borrego, M.] Hosp Univ Virgen del Rocio, Oncol, Seville, Spain | |
dc.contributor.authoraffiliation | [Marx, G.] Univ Sydney, Med Oncol, Sydney, NSW, Australia | |
dc.contributor.authoraffiliation | [Brufsky, A.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Oncol, Pittsburgh, PA USA | |
dc.contributor.authoraffiliation | [Chien, A. J.] Univ Calif San Francisco, Med Oncol, San Francisco, CA 94143 USA | |
dc.contributor.authoraffiliation | [Thirlwell, M. P.] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Med Med Oncol Dept, Glen Site, Montreal, PQ, Canada | |
dc.contributor.authoraffiliation | [Trudeau, M. E.] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Med Oncol, Toronto, ON, Canada | |
dc.contributor.authoraffiliation | [Bose, R.] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA | |
dc.contributor.authoraffiliation | [Saenz, J. A. Garcia] Hosp Clin Univ San Carlos, Med Oncol, Madrid, Spain | |
dc.contributor.authoraffiliation | [Egle, D.] Univ Frauenklin Innsbruck, Gynaecol, Innsbruck, Austria | |
dc.contributor.authoraffiliation | [Pistilli, B.] Gustave Roussy Canc Ctr, Breast Canc Grp, Villejuif, France | |
dc.contributor.authoraffiliation | [Wassermann, J.] Hop La Pitie Salpetriere, Med Oncol, Paris, France | |
dc.contributor.authoraffiliation | [Cheong, K. A.] Adelaide Canc Ctr, Med Oncol, Adelaide, SA, Australia | |
dc.contributor.authoraffiliation | [Semsek, D.] Praxis Diakonie Krankenhaus Onkol Schwerpunktprax, Med Oncol, Fribourg, Switzerland | |
dc.contributor.authoraffiliation | [Singer, C. F.] Med Univ Vienna, Med Oncol, Vienna, Austria | |
dc.contributor.authoraffiliation | [Diprimeo, D.] Puma Biotechnol Inc, Biostat, San Francisco, CA USA | |
dc.contributor.authoraffiliation | [Foruzan, N.] Puma Biotechnol Inc, Clin Operat, San Francisco, CA USA | |
dc.contributor.authoraffiliation | [McCulloch, L. M.] Puma Biotechnol Inc, Clin Sci Dept, San Francisco, CA USA | |
dc.contributor.authoraffiliation | [Barcenas, C. H.] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX 77030 USA | |
dc.date.accessioned | 2023-05-03T14:39:56Z | |
dc.date.available | 2023-05-03T14:39:56Z | |
dc.date.issued | 2022-05-05 | |
dc.identifier.doi | 10.1016/j.annonc.2022.03.089 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.unpaywallURL | http://www.annalsofoncology.org/article/S0923753422004689/pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/21900 | |
dc.identifier.wosID | 792494100075 | |
dc.issue.number | 3 | |
dc.journal.title | Annals of oncology | |
dc.journal.titleabbreviation | Ann. oncol. | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | S156-S156 | |
dc.publisher | Elsevier | |
dc.rights.accessRights | open access | |
dc.title | Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Final findings from the CONTROL trial | |
dc.type | conference output | |
dc.type.hasVersion | VoR | |
dc.volume.number | 33 | |
dc.wostype | Meeting Abstract | |
dspace.entity.type | Publication |